Health & Medicine Chinese Doctors Are Using Modified T-Cells to Treat Advanced Forms of Cancer National Cancer Institute In Brief by Kyree Leary Shixiu Wu, president of the Hangzhou Cancer Hospital, has started treating patients with advanced forms of cancer with modified T-cells. Despite his success, others worry China's lack of tight research regulations could be putting patients at risk. According to China’s National Central Cancer Registry, Esophageal cancer is one of the most common forms of cancer in China. Like many other types, cancer of the esophagus can be treated with chemotherapy. But, as is also true of other forms of cancer, chemotherapy isn’t always successful. In China, and around the world, there’s a great need for the development of new treatments. Dr. Shixiu Wu, president of the Hangzhou Cancer Hospital, has tested a somewhat new treatment that takes a patient’s T-cells from the body, genetically edits them to target cancerous cells, then puts the altered cells back. If the process sounds at all familiar, it’s probably because using T-cells in this manner was approved by the U.S. Food and Drug Administration back in August 2017. We reported on a pair of CAR-T studies in December that used T-cells to fight cancer, as will the first CRISPR trial set to take place in the United States. The other research involving modified T-cells to fight cancer doesn’t diminish the impact of Wu’s work, though. In fact, Wu believes the study is one of the most advanced involving CRISPR in China. Currently, Wu’s T-cell treatment is being tested on 21 people with advanced Esophageal cancer that didn’t respond to other treatments. So far, 40 percent of his patients have responded positively to the new treatment.